Board summary
Key figures
36,483
Registered population
54.5% aged 18–64
27.1%
Aged 65+
ICB 21.9% · England 17.9%
6.5%
Ethnic minority (non-White)
2.2% Asian · England 9.6%
8.3%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,923
Core20 residents (est.)
Resident basis; registered basis ~2,890 · see page 3
6,393
Hypertension register
+5.17% in 3 yrs · England +5.60%
337
SMI register
20.8% of Eastbourne's
892
COPD register
Reviews +11.42% in 3 yrs
Forecast to 2030
7,054
Hypertension patients, 2030
+661 on today
70.8%
QRISK ≥20% on statins, 2030
+4.08pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension and lipid control trail England.
Hypertension treatment to target is 66.6% (England 70.3%), under-80 BP control 63.5% (England 67.8%), and QRISK ≥ 20% lipid therapy 61.8% (England 63.6%).
Age-five MMR drops between doses.
Age-5 MMR coverage drops 10.9 pp from 90.6% at dose 1 to 79.7% at dose 2 (England 82.8%, NHS Sussex ICB 87.1%, target 95.0%).
Asthma review rate rose over three years.
Asthma reviews rose +35.4% over 2023 to 2025 to 66.7% (England 65.7%), though an estimated 806 of 2,421 registered patients remain unreviewed.
Population, age and ethnicity
Registered patients aged 65+ reach 27.1%, well above England's 17.9% average
Across three practices serving 36,483 registered patients, 27.1% (9,906) are aged 65+, above Eastbourne (24.2%), NHS Sussex ICB (21.9%) and England (17.9%). Working-age adults (18–64) comprise 54.5% (Eastbourne 58.6%, ICB 60.5%, England 62.7%) and children (0–17) 18.3% (Eastbourne 17.2%, ICB 17.7%, England 19.6%). Census resident data indicates 93.5% White ethnicity (Eastbourne 90.8%, ICB 91.0%, England 81.1%), with a 6.5% ethnic minority share. Projected list growth to 2030 is an unverified 0.6% (Eastbourne 1.1%, ICB 2.1%, England 2.3%). This older profile may elevate PCN chronic disease burden.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Eastbourne local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Eastbourne LA) | 2,325 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Eastbourne LA) | 1,221 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Eastbourne LA) | 7.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 8.3% overall but reaches 14.25% at Harbour Medical Practice
The PCN Core20 share is 8.3% (about 2,900 residents), below Eastbourne (19.5%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Weighted practice share is 7.9%. Across captured practices, the Core20 range is 8.7 pp. Stone Cross Surgery records 5.59% (847 estimated patients). Sovereign Practice records 6.99% (960 estimated patients). Harbour Medical Practice leads at 14.25% (1,083 estimated patients). Proactive outreach and multi-condition reviews should prioritise practice Core20 workload rather than applying a flat PCN allocation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
337
SMI register
0.94% recorded prevalence
198
Learning disability register
0.55% recorded prevalence
16
Care homes, 718 beds
In the PCN catchment
9.7%
Provide unpaid care
Eastbourne, Census 2021
The PCN records 337 patients on the severe mental illness register (0.9%, Eastbourne 1.5%, NHS Sussex ICB 1.1%, England 1.0%) and 198 with learning disabilities (0.6%, Eastbourne 0.8%, ICB 0.6%, England 0.6%). Catchment care homes provide 718 beds across 16 sites; Eastbourne recorded 29 rough sleepers in autumn 2025.
Severe mental illness: physical health checks
SMI physical health checks trail England for blood pressure (79.3% vs 83.4%), BMI (76.8% vs 82.1%) and alcohol recording (76.8% vs 81.8%), with blood pressure checks at Stone Cross Surgery at 69.5%, which may reflect recall gaps to audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,393
Hypertension register
+5.17%
Register growth, 3 yrs
Eastbourne +5.24% · England +5.60%
+3.77pp
BP control, under 80
≤140/90 · +0.37pp aged 80+
+661
More patients by 2030
Forecast 7,054 (19.71%)
Hypertension case-finding and control
Hypertension prevalence is 17.8% (6,393 patients), above Eastbourne (17.5%), NHS Sussex ICB (16.3%) and England (15.2%). Recent blood pressure recording reaches 88.3% (England 90.0%). However, treatment to target is 66.6% (England 70.3%), with control in under-80s at 63.5% (England 67.8%) and in ages 80+ at 77.8% (England 81.2%). By practice, under-80 control ranges from 62.4% at Stone Cross Surgery to 63.8% at Sovereign Practice and 64.7% at Harbour Medical Practice. Crude prevalence is not age-adjusted. Blood pressure control trails national benchmarks despite high recorded prevalence, which may reflect medication titration or recall gaps to test through audit.
Lipids and statins
Statin coverage for QRISK 20% or higher is 61.8% (England 63.6%, Eastbourne 60.9%, NHS Sussex ICB 60.0%). For patients with diabetes and CVD, statin treatment is 81.7% (England 84.4%), falling 1.4% over 2023 to 2025 (England +1.0%). Lower coverage may reflect follow-up gaps to test through clinical audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 75,338 | £2.00 | £2.42 | £1.86 | £150,676 |
| Cardiovascular (all), 2025 | 101,025 | £2.70 | £3.32 | £3.33 | £272,768 |
In 2026, the PCN prescribed 75,338 lipid-regulating items at £2.00 per item (£150,676 spend), compared with £1.86 in England, £2.09 in Eastbourne and £2.42 in NHS Sussex ICB. Spend was £10,547 more than at England's unit cost, but £31,642 less than at NHS Sussex Integrated Care Board's.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+35.40%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.61%
Asthma prevalence, PCN 3-yr % change
Asthma QOF prevalence is 7.1% (2,421 patients). Annual reviews rose +35.4% over 2023 to 2025 (England +4.4%) to 66.7% (England 65.7%), leaving an estimated 806 patients without a recorded review. Prescribing of asthma management items for ages 5–19 is 2,293 per 1,000 (England 1,488; Eastbourne 2,006). COPD prevalence is 2.5% (892 patients), while annual reviews trail England at 71.9% (England 76.4%, NHS Sussex ICB 74.2%), which may indicate follow-up gaps to audit.
Cancer register and children's immunisation
Cancer QOF prevalence is 5.2% (1,863 patients; England 3.8%). In Q1 2025/26, age-5 MMR coverage drops 10.9 pp from dose 1 (90.6%) to dose 2 (79.7%, trailing England's 82.8% and below the 95.0% target by 15.3 pp). Pre-school 4-in-1 booster coverage also matches 79.7% across 64 children. Drop-off between doses may reflect recall barriers to test through audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, exceeding England (55.3%) by 3.2 percentage points but sitting 16.5 pp below the 75.0% national ambition by 2028. Staging completeness was 64.3% (8,209 of 12,766 registered cancers), meaning staging is incomplete and site-specific counts can be small. Reaching the ambition requires about 1,360 additional early-stage diagnoses annually across the ICB. While the early-stage share increased +5 pp from 53.4% in 2013, early diagnosis remains lower in lung (30.3%) and bowel (49.8%). These system metrics do not reflect PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, East Sussex Healthcare NHS Trust achieved 84.2% on the 28-day faster diagnosis standard (standard 75.0%), ahead of University Hospitals Sussex NHS Foundation Trust (74.0%), Maidstone and Tunbridge Wells NHS Trust (81.8%), NHS Surrey and Sussex Integrated Care Board (79.3%) and England (79.3%). The trust met the 31-day standard at 98.2% (standard 96.0%). However, 62-day referral to treatment was 67.0%, 18.0 pp below the 85.0% standard (ICB 71.5%, England 71.2%). Trust diagnostic 6-week waits were 5.3% (England 23.1%). These hospital metrics do not reflect PCN performance.
| Pathways within standard (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 74.01 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 76.79 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 65.20 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 6.48 | 5.62 | 0.92 | 21.40 |
| CT | 0.48 | 8.57 | 0.51 | 9.92 |
| Echocardiography | 21.94 | 0.39 | 2.57 | 28.48 |
| Colonoscopy | 0.74 | 39.35 | 19.80 | 30.83 |
| Gastroscopy | 0.31 | 20.02 | 24.03 | 29.02 |
| All 15 DM01 tests | 5.27 | 12.95 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In June 2026, provisional community services statistics recorded 105,045 care activities and 100,740 care contacts across 25,880 patients residing in East Sussex, alongside 316,320 activities and 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Adults aged 65+ accounted for 68% of East Sussex contacts (68,465 contacts). These local authority figures reflect wider community activity, not PCN performance.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement exceeded England (92.5%), from 93.4% at Sovereign Practice to 99.2% at Stone Cross Surgery. Vaccination achievement spanned 27.7 pp, from 71.2% at Sovereign Practice to 98.9% at Stone Cross Surgery (England 55.2%), which may reflect variation in recall systems to test via practice audit.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Harbour Medical | 114 | 14.2 | 49.1% | 68.6% | 74.5% |
| Stone Cross | 117 | 5.6 | 40.0% | 75.2% | 72.9% |
| Sovereign Practice | 103 | 7.0 | 28.2% | 71.3% | 68.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight measures trail England over three years, led by heart failure reviews
Across 25 compared measures, eight trail England's three-year trajectory over 2023 to 2025. Annual heart failure reviews fell 2.2% (England +8.7%, Eastbourne +4.1%), though recorded coverage is 81.4% (England 78.5%). Offers of smoking cessation support fell 3.1 pp (England +0.1 pp), alongside recorded coverage of 95.1% (England 94.2%). Statin treatment in diabetes with cardiovascular disease fell 1.4% (England +1.0%). Conversely, three-year gains outpaced England in asthma reviews (+35.4% vs +4.4%) and COPD reviews (+11.4% vs +2.8%). Slower progress in cardiovascular processes may reflect review slippage that structured recall audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Smoking support (SMI)
Diabetes statin (CVD)
BP control, 80+
Learning disability register
Asthma reviews
Alcohol record (psychosis)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Eastbourne | Asset | PCN | Eastbourne |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (718 beds) | n/a | Schools (catchment) | 24 | n/a |
| Children's centres | 1 | 2 | Places of worship | 14 | 46 |
| Libraries | 1 | 3 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 8 | Primary academies | 8 | 22 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school MMR and booster recall
In Q1 2025/26 across 64 children aged 5, MMR coverage drops 10.9 pp from 90.6% at dose 1 to 79.7% at dose 2 (England 82.8%, NHS Sussex ICB 87.1%). For discussion: practices could audit age-five cohorts missing second MMR and 4-in-1 booster doses and test reminder contacts before school entry. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured asthma annual review recall
Asthma review coverage is 66.7% (England 65.7%, Eastbourne 52.3% after +35.4% growth over 2023 to 2025), leaving an estimated 806 of 2,421 registered patients unreviewed. For discussion: the PCN could run structured asthma recall using a single review template alongside inhaler checks, prioritising higher Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Learning disability register validation
Learning disability QOF prevalence is 0.6% (198 patients), matching England (0.6%) and NHS Sussex ICB (0.6%) but below Eastbourne (0.8%), with an unadjusted gap range of +16 to +86 patients. For discussion: practices could validate learning disability coding against clinical records and explore social-care record cross-checking where data sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 proactive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Second dose MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Primary care cancer safety netting (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Pre-school MMR and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
